Ben has more than 20 years of experience working in biopharma business development and M&A, and pipeline and launch strategy.

Ben is an expert in preparing for launch. He has supported TA strategy, pipeline life cycle management and disease/condition strategy, global opportunity assessment and valuation, asset and company diligence, and pipeline asset strategy. Ben has worked across every major therapeutic area with a particular focus in oncology, immunology, central nervous system and rare disease. Ben has presented at Bio International in 2017 and 2019, Bio Europe in 2019, and at private events during the JP Morgan Conference in 2019 and 2020. 

Ben’s areas of expertise include preparing to launch, emerging pharma “first launch,” global opportunity assessment and valuation, therapeutic area strategy, disease and condition strategy, pipeline life cycle management and optimization, asset and company due diligence, asset/technology and company identification for licensing or acquisition, market entry strategy, and innovation and growth strategy. 

Prior to ZS, Ben was a partner at Monitor Group, the founder of Hohn & Company, and a principal at ISO Healthcare Consulting.

Ben holds an MBA from Boston University with the highest honors and a bachelor’s in economics and pre-med from Vassar College.